Progression of non-small cell lung cancer: Diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 469-473

  Kanoh, Yuhsaku ^a   Abe, Tadashi ^c   Masuda, Noriyuki ^b   Akahoshi, Tohru ^b  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

C reactive protein; Matrix metalloproteinase 2; Non small cell lung cancer; Serum amyloid A

Indexed keywords

C REACTIVE PROTEIN; GELATINASE A; SERUM AMYLOID A;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME IMMUNOASSAY; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; MALE; METASTASIS POTENTIAL; NEPHELOMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR LOCALIZATION; UNIVERSITY HOSPITAL;

AGED; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; SERUM AMYLOID A PROTEIN; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84872782068     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2123     Document Type: Article

References (34)

1. Baramova EN, Bajou K, Remacie A, L'Hoir C, Krell HW, Weidle UH and Foidart JM: Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405: 157-162, 1997. (Pubitemid 27136502)
2. Monea S, Lehit K, Keski-Oja and Mignatii P: Plasmin activates pro-matrix metalloproteinases-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 192: 160-170, 2002. (Pubitemid 34747784)
3. Arbeláez LF, Bergmann U, Tuuttila A, Shanbhag VP and Stigbrand T: Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and α2-macroglobulin. Arch Biochem Biophys 347: 62-68, 1997. (Pubitemid 27484021)
4. Beekman B, Drijfhout JW, Ronday HK and Tekoppele JM: Fluorogenic MMP activity assay for plasma including MMPs complexed to α2-macroglobulin. Ann NY Acad Sci 878: 150-156, 1999.
5. Chen WT and Wang JY: Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2 and TIMP-2 localization. Ann NY Acad Sci 878: 361-370, 1999.
6. Ding S, Zhang M, Zhao Y, Chen W, Yao G, Zhang C, Zhang P and Zhang Y: The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke. Am J Med Sci 336: 27-31, 2008.
7. Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J and Matas M: Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 40: 469-475, 2004. (Pubitemid 39165021)
8. Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, Egawa S and Baba S: Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 22: 1813-1818, 2002.
9. Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Changes of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency. Clin Lab 58: 217-225, 2012.
10. Kanoh Y and Ohtani H: Levels of interleukin-6, CRP and α2-macrogloburin in cerebrospinal fluid (CSF) and serum as indicator of blood-CSF barrier damage. Biochem Mol Biol Int 43: 269-278, 1997. (Pubitemid 28297129)
11. dos Anjos BL and Grotto HZ: Evaluation of C-reactive protein and serum amyloid A in the detection of inflammatory and infectious disease in children. Clin Chem Lab Med 48: 493-499, 2010.
12. Fujiwara H, Suchi K, Okamura H, Umehara S, Toda M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T and Otsuji E: Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 103: 62 - 68, 2011.
13. Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G and Trinchero R: Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implication for the diagnosis, therapy, and prognosis of pericarditis. Circulation 213: 1092-1097, 2011.
14. Kablak-Ziembicka A, Przewlocki T, Sokolowski A, Tracz W and Podolec P: Carotid intima-media thickness, hs-CRP and TNF-α are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis 214: 185-190, 2011.
15. Kanoh Y, Ohara T and Akahoshi T: Acute inflammatory biomarkers in cerebrospinal fluid as indicators of blood cerebrospinal fluid barrier damage in Japanese subjects with infectious meningitis. Clin Lab 57: 37-46, 2011.
16. Smith JW, Colombo JL and McDonald TL: Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid cystic fubrosis patients. J Clin Lab Anal 6: 219-224, 1992.
17. Yap SH, Moshage HJ, Hazenberg BP, Roelofs MH, Bijizet J, Limburg PC, Aarden LA and van Rijiswijk MH: Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1091: 405-408, 1991.
18. Smith JW and McDonald TL: Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone. Clin Exp Immunol 90: 293-299, 1992.
19. Matsuda T, Hirano T, Nagasawa S and Kishimoto T: Identification of α2 macroglobulin as a carrier protein for IL-6. J Immunol 142: 148-152, 1989. (Pubitemid 19034735)
20. Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol 39: 1553-1558, 2011.
21. Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Clinicopathological characteristic of androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol 41: 39-45, 2012.
22. Mountain C: A new international staging system for lung cancer. Chest 89: S225-S233, 1986.
23. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y and Hayakawa T: A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 221: 91-103, 1993. (Pubitemid 24022824)
24. Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC and Rha SY: MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology 58: 2015-2019, 2011.
25. Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC and Rha SY: Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Oncol Lett 3: 699-703. 2012.
26. Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska V: Expression of MMP-7, MMP-9 TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res 29: 2513-2517, 2009.
27. Peng WJ, Zhang JQ, Wang BX, Pan HE, Lu MM and Wang J: Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clin Chim Acta 413: 1121-1126, 2012
28. Bataille R, Boccadoro M, Klein B, Durie and Pileri A: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733-737, 1992.
29. Firooz N, Albert D, Wallace D, Ishimori M, Berel D and Weisman M: High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus 20: 588-597, 2011.
30. Chua TC, Chong CH, Liauw W, Zhao J and Morris DL: Inflammation markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg 256: 342-349, 2012.
31. O'Dowd C, McRae LA, McMillian DC, Kirk A and Milroy R: Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 5: 988-992, 2010.
32. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC and Chen JH: Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 14: 84-93, 2007.
33. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratanr E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S and Santin AD: Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer 101: 335-341, 2009.
34. Liu C, Pan C, Shen J, Wang H and Yong L: Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. Oncol Lett 3: 1259-1262, 2012.